# EDGAR Filing Document

**Accession Number:** 0001769759
**File Stem:** 0001104659-25-066301
**Filing Date:** 2025-7
**Character Count:** 11506
**Document Hash:** 405a71330b41d3bd0fdfa8f3f96f399e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-066301.hdr.sgml**: 20250708

**ACCESSION NUMBER**: 0001104659-25-066301

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250707

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250708

**DATE AS OF CHANGE**: 20250708

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Monogram Technologies Inc.
- **CENTRAL INDEX KEY:** 0001769759
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 812349540
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41707
- **FILM NUMBER:** 251109607

**BUSINESS ADDRESS:**
- **STREET 1:** 53 BRIDGE STREET UNIT 507
- **CITY:** BROOKLYN
- **STATE:** NY
- **ZIP:** 11201
- **BUSINESS PHONE:** (718) 576-3205

**MAIL ADDRESS:**
- **STREET 1:** 3913 TODD LANE
- **STREET 2:** SUITE 307
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78744

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MONOGRAM ORTHOPAEDICS INC
- **DATE OF NAME CHANGE:** 20190305

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): July 7, 2025**

**Monogram Technologies Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41707** | **81-3777260** |
| **(State or other jurisdiction <br> of incorporation)** | **(Commission<br> File Number)** | **(I.R.S. Employer<br> Identification Number)** |

---

**3919 Todd Lane** **, Austin, TX 78744**

**(Address of principal executive offices, including zip code)**

**Registrant's telephone number, including area code: (512) 399-2656**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading <br> Symbol(s)** | **Name of each exchange<br> on which registered** |
| **Common Stock, par value $0.001 per share** | **MGRM** | **The Nasdaq Stock Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 3.03** | **Material Modification to Rights of Security Holders** |

---

As previously disclosed, Monogram Technologies Inc. (the "Company") previously issued and sold units, with each unit consisting of (a) one share of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") and (b) one common stock purchase warrant to purchase one share of the Company's common stock, $0.001 par value per share (the "Common Stock"), in connection with a registered public offering that closed on October 1, 2024 (the "Offering"). Each share of Series D Preferred Stock is convertible into one share of the Company's Common Stock. Pursuant to the Certificate of Designation of Preferences, Rights and Limitations (the "Certificate of Designation"), of the Series D Preferred Stock subject to certain exceptions and limitations, the Company has the right to direct the mandatory conversion (the "Mandatory Conversion") of the Series D Preferred Stock in certain events, including in the event that the closing price of the Common Stock closes at or above $2.8125 per share for ten (10) consecutive trading days ending and including the applicable Mandatory Conversion Notice Date (as defined below).

On July 7, 2025 (the "Mandatory Conversion Notice Date") the Company electronically mailed to the holders of Series D Preferred Stock (the "Holders"), a Mandatory Conversion Notice (as defined in the Certificate of Designation) notifying the Holders that, in accordance with Section 6(a) of the Certificate of Designation, the closing price of the Common Stock closed at or above $2.8125 per share for ten (10) consecutive trading days ending and including the Mandatory Conversion Notice Date, thereby trigging a Mandatory Conversion pursuant to Section 6(a) of the Certificate of Designation. Such conversion shall be effective as of July 14, 2025.

The foregoing summary of the Certificate of Designation does not purport to be complete and is subject to, and qualified in its entirety by, such document attached as Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 12, 2024, which is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events** |

---

On July 8, 2025, the Company issued a press release announcing the mailing of the Notice of Conversion, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](tm2516378d2_ex99-1.htm) | [Press Release dated July 8, 2025.](tm2516378d2_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
|  | **MONOGRAM TECHNOLOGIES INC.** |
| Dated: July 8, 2025 | /s/ Benjamin Sexson |
|  | Benjamin Sexson |
|  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm2516378d2_ex99-1img01.jpg)

**Monogram Technologies Announces the Mandatory Conversion of** 

**8.00% Series D Convertible Cumulative Preferred Stock** 

**AUSTIN, TX – July 8, 2025** - Monogram Technologies Inc. (NASDAQ: MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced the mandatory conversion of all outstanding shares of 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") that were issued in connection with the Company's offering that closed on October 1, 2024 (the "Offering"). During the Offering, the Company issued and sold units, with each unit consisting of (a) one share of the Company's Series D Preferred Stock and (b) one common stock purchase warrant to purchase one share of the Company's common stock, $0.001 par value per share (the "Common Stock"),

On July 7, 2025, the Company sent a notice of mandatory conversion to all holders of Series D Preferred Stock notifying such holders that, in accordance with Section 6(a) of the Certificate of Designation of Preferences, Rights and Limitations (the "Certificate of Designation") of the Series D Preferred Stock, the closing price of the Common Stock closed at or above $2.8125 per share for ten (10) consecutive trading day ending and including July 7, 2025s, thereby trigging a Mandatory Conversion (as defined in the Certificate of Designation) pursuant to Section 6(a) of the Certificate of Designation. Such conversion shall be effective as of July 14, 2025.

**About Monogram Technologies Inc.**

Monogram Technologies (NASDAQ: MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics.

Monograms mBôs<sup>TM</sup> precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced, better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored.

Monogram has obtained FDA 510(k) clearance for its mBôs TKA System and FDA clearance for its mPress implants. The Company is required to obtain FDA clearance before it can market its products.

The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation.

To learn more, visit <u>www.monogramtechnologies.com</u>.

**Forward-Looking Statements**

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the Company's filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

**Investor Relations**

Chris Tyson<br> Executive Vice President<br> MZ North America<br> Direct: 949-491-8235<br> <u>MGRM@mzgroup.us</u>